… Previously reported data from vaccination with 10 μg or 30 μg of BNT162b1 in adults 18 to
… Covid-19 vaccine candidate. Consistent with our strategy to evaluate several RNA vaccine …

… Previously reported data from vaccination of 18–55 year old adults with 10 μg or 30 μg of …
COVID-19 vaccine candidate. Consistent with our strategy to evaluate several RNA vaccine …

… are currently available to prevent SARS-CoV-2 infection or COVID-19. The RNA vaccine
platform has enabled rapid vaccine development in response to this pandemic. RNA vaccines …

… proof of concept that RNA-based vaccines are a promising … speed with which an RNA-based
vaccine can be developed with … a practical demonstration that RNA-based vaccines, which …

… in the initial messenger RNA COVID-19 vaccine trials, although … COVID-19 vaccine has
been reported. In this series, we detail the occurrence of myocarditis after COVID-19 vaccination …

… 29, 2020, seven potential RNA based COVID-19 vaccines are in different stages of clinical
… the rationality of RNA as a platform for vaccine development against COVID-19, highlighting …

… RNA (mRNA) COVID-19 vaccines (1). Consequently, despite standard vaccination with mRNA
vaccines, … to receive a third dose of mRNA vaccine after the standard 2-dose regimen to …

… of a modRNA vaccine or any COVID-19 vaccine. In fact, some … COVID-19 vaccines arise,
namely what can be the impact of the new SARS-CoV-2 circulating variants on the vaccine…

… RNA (mRNA) COVID-19 vaccines have … COVID-19 vaccine after a first-dose reaction. In
this study, we examine the safety of the second dose of Pfizer-BioNTech or Moderna vaccine in …

… COVID-19, mRNA vaccines … vaccines in the context of the COVID-19 pandemic. Furthermore,
we address current research using the technology and future directions of mRNA vaccine …